VMQ StocksFor the value investor looking to harness academic research in
an actively managed portfolio
Bits and BipsNewsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Learn more about Cardio Diagnostics Holdings Inc's (CDIO) stock grades for Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Jack Gilleland
Financial Summary
Share Statistics
CDIO
Industry Median
Percentile (All Stocks)
Market Cap (Mil)
$6.6
$286.3
4%
Shares Out (Mil)
3.0
54.2
10%
Institutional Ownership
70.8%
92.8%
43%
Float (Mil)
2.8
39.7
7%
Beta
2.22
0.94
95%
Avg Daily Volume (000s)
77
534
32%
Price Change (52-week)
(39.5%)
58.7%
19%
Growth
CDIO
Industry Median
Percentile (All Stocks)
Sales (5yr)
na
13.6%
na
Net Income (5yr)
(61.0%)
(10.1%)
5%
EPS (5yr)
26.7%
16.0%
77
Dividends (5yr)
na
0.0%
0%
Cash Flow (5yr)
(17.4%)
(15.6%)
40%
Estimates
Qtrly
Current Fiscal Year
Next Fiscal Year
# of Estimates
na
na
na
Current EPS
na
na
na
Month Ago EPS
na
na
na
# Rev Up
na
na
na
# Rev Down
na
na
na
Three Months Ago EPS
na
na
na
Year/Year Chg
na
na
na
Financials
CDIO
Industry Median
Percentile (All Stocks)
Sales (TTM) (Mil)
na
$37
na
Net Income (TTM) (Mil)
($7)
($43)
32%
EPS (TTM)
($2.759)
($1.400)
12%
Operating Cash Flow (TTM) (Mil)
($6)
($31)
24%
Net Cash Flow (TTM) (Mil)
($2)
$2
37%
Long-Term Debt (Q1) (Mil)
$0
$4
10%
Enterprise Value (Q1) (Mil)
$1
$160
4%
Valuation
CDIO
Industry Median
Percentile (All Stocks)
P/B
0.88
2.77
18%
P/E
na
19.1
na
Dividend Yield
0.0%
0.0%
0%
PEG (5yr hist)
na
1.0
na
Ratios
CDIO
Industry Median
Percentile (All Stocks)
Gross Margin
100.0%
64.2%
96%
Net Margin
na
(75.9%)
na
ROA
(70.6%)
(47.3%)
8%
ROE
(75.4%)
(55.0%)
12%
Liabilities to Assets
6.3%
29.6%
3%
F-Score
4
2
34%
Cardio Diagnostics Holdings, Inc. did not pass any screens on 8/20/2026.
Looking for access to this powerful feature? Take the first step in becoming an A+ Investor today.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors